Form 4: Glaukos Corp President & COO Acquires Shares Through Stock Option Vesting

Joseph E. Gilliam, President & COO of Glaukos Corporation, reports the acquisition of 14,640 shares through the vesting of a stock option related to the achievement of operational targets.

Summary

• On September 19, 2024, Joseph E. Gilliam, the President & COO of Glaukos Corporation, acquired 14,640 shares of common stock through the vesting of a stock option.
• This option was initially granted on March 24, 2022, and its vesting was contingent upon Glaukos achieving certain operational targets over a multi-year period.
• The Compensation, Nominating and Governance Committee determined on September 19, 2024, that these targets had been met, leading to the vesting of a portion of the option.
• The exercise price of the stock option is $55.18.
• Following this transaction, Gilliam directly owns 50,379 shares of Glaukos Corp.
• The acquired shares will vest in four tranches: 25% in September 2024, 25% in December 2024, 25% in May 2025, and the remaining 25% in September 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the vesting of stock options indicates the achievement of operational targets, suggesting the company is performing well. However, it's a routine filing and doesn't contain groundbreaking news.

Positives

• The vesting of the stock option indicates that Glaukos Corporation has achieved certain operational targets, which is a positive sign for the company's performance.
• The vesting schedule incentivizes continued performance from the executive.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the option suggests confidence in the company's continued operational performance.

Industry Context

Executive stock option grants and vesting are common practices in publicly traded companies to align management's interests with those of shareholders. The achievement of operational targets leading to vesting suggests the company is executing its strategic plan.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and medical device industries, similar to companies like Alcon, Johnson & Johnson (in their medical device segments), and others in the ophthalmic space.
• Vesting schedules tied to performance metrics are also common, ensuring executives are rewarded for achieving specific goals that benefit the company and its shareholders.

Stakeholder Impact

• Shareholders may view the vesting of stock options positively, as it indicates the company is achieving its operational goals.
• Employees may be motivated by the company's success in meeting its targets.

Key Dates